Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
OpenAI Rejects Apple Trade Secret Theft Claims 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Add as a preferred source on Google
MODI’IN, Israel and MANASQUAN, N.J., March 09, 2018 -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced that management will be participating in the following healthcare investor conferences:
- Barclays Global Healthcare Conference – Loews Miami Beach Hotel in Florida (March 13-15, 2018). Members of the management team will participate in one-on-one meetings with investors on Wednesday and Thursday, March 14-15.
- H.C. Wainwright & Co. 2nd Annual NASH Investor Conference – St. Regis Hotel in New York (March 19, 2018). Chief Executive Officer Raffi Werner will deliver a company presentation at 2:00pm ET and members of the management team will participate in one-on-one meetings with investors.
- Oppenheimer 28th Annual Healthcare Conference — The Westin New York Grand Central (March 20-21, 2018). Mr. Werner will deliver a company presentation at 4:30pm ET on Tuesday, March 20 and members of the management team will participate in one-on-one meetings with investors that day.
About Exalenz Bioscience
Exalenz Bioscience develops and markets diagnostic tests and monitoring systems that use the breath to diagnose and help manage gastrointestinal and liver conditions. The company’s flagship BreathID® Hp offers the most efficient and accurate test for detection of H. pylori bacteria, associated with various illnesses including gastric cancer, and is already in use in over 400 U.S. medical centers and major labs across the country. The BreathID 13C-methacetin breath test (MBT) is a sensitive, noninvasive, point of care tool that measures the microsomal function of the liver. Exalenz holds regulatory approvals in Europe, the United States, China and Israel for H. pylori detection and is currently evaluating additional applications of the BreathID platform, including MBT in the detection of CSPH in patients with NASH. Additional information is available at www.exalenz.com.
Contact Information
Investor Relations
David Carey
212-867-1768
[email protected]
Media
Glenn Silver
646-871-8485
[email protected]
